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IL-36γ Augments Host Defense and
Immune Responses in Human
Female Reproductive Tract Epithelial
Cells
Sean M. Winkle, Andrea L. Throop and Melissa M. Herbst-Kralovetz*
Department of Basic Medical Sciences, College of Medicine–Phoenix, University of Arizona, Phoenix, AZ, USA
IL-36γ is a proinflamatory cytokine which belongs to the IL-1 family of cytokines. It is
expressed in the skin and by epithelial cells (ECs) lining lung and gut tissue. We used
human 3-D organotypic cells, that recapitulate either in vivo human vaginal or cervical
tissue, to explore the possible role of IL-36γ in host defense against pathogens in the
human female reproductive tract (FRT). EC were exposed to compounds derived from
virus or bacterial sources and induction and regulation of IL-36γ and its receptor was
determined. Polyinosinic-polycytidylic acid (poly I:C), flagellin, and synthetic lipoprotein
(FSL-1) significantly induced expression of IL-36γ in a dose-dependent manner, and
appeared to be TLR-dependent. Recombinant IL-36γ treatment resulted in self-
amplification of IL-36γ and its receptor (IL-36R) via increased gene expression, and
promoted other inflammatory signaling pathways. This is the first report to demonstrate
that the IL-36 receptor and IL-36γ are present in the human FRT EC and that they are
differentially induced by microbial products at this site. We conclude that IL-36γ is a
driver for epithelial and immune activation following microbial insult and, as such, may
play a critical role in host defense in the FRT.
Keywords: IL-1 family, IL-36γ, human epithelial cells, antimicrobial peptides, innate immunity, IL-36 receptor,
microbial products, inflammatory mediators
INTRODUCTION
The epithelium of the human FRT plays host to a wide variety of commensal bacteria and acts
as a first responder to invading microbes and changes in the microbial milieu. The human FRT
can be divided into two distinct regions that differ in cellular structure and function. The lower
FRT epithelium is composed of the vagina and ectocervix and is lined with a stratified squamous
epithelium built to resist physical and mechanical stress. The upper FRT epithelium is made up
of a single layer of columnar EC and includes the endocervix, endometrium, fallopian tubes, and
the uterus (Horne et al., 2008). Site-specific differences in the magnitude and pattern of immune
response have been investigated in the vagina and endocervix (Quayle, 2002; Pudney et al., 2005;
Herbst-Kralovetz et al., 2008).
Abbreviations: ECs, epithelial cells; FRT, female reproductive tract; FSL-1, fibroblast stimulating lipopeptide-1; IL-36,
interleukin-36; IL-36R, IL-36 receptor, KSFM, keratinocyte serum-free medium; PBST, PBS-0.05%Tween-20; qRT-PCR,
quantitative real-time polymerase chain reaction; rIL-36γ, recombinant IL-36γ, STI, sexually transmitted infection.
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To better understand immune function of the human FRT at
these two sites, we investigated a newly characterized IL-1 family
member identified to play a role in chronic inflammation and
disease at other mucosal sites (Dunn et al., 2001; Gabay and
Towne, 2015). The IL-36 family is a group of cytokines whose
members are known for their role in mediating inflammation and
host defense (Dunn et al., 2001; Gresnigt and van de Veerdonk,
2013; Gresnigt et al., 2013). While IL-36 family members have
been shown to be expressed and secreted by the epithelium lining
the lungs, gut and skin, this family, to our knowledge, has not
previously been investigated in the human FRT (Chustz et al.,
2011; Johnston et al., 2011; Gabay and Towne, 2015; Medina-
Contreras et al., 2016). There are three isoforms that comprise
the IL-36 family; IL-36α (IL-1F7), IL-36β (IL-1F8), and IL-36γ
(IL-1F9) and these cytokines are expressed in a more tissue-
restricted fashion relative to IL-1 (Dunn et al., 2001; Gresnigt
and van de Veerdonk, 2013). Of the three isoforms, IL-36γ has
the highest expression levels in damaged or infected epithelium
that lines the skin and lungs suggesting that it plays a role in
epithelial immune response (Berglof et al., 2003; Lian et al., 2012;
Gabay and Towne, 2015). As tissue becomes diseased, IL-36γ
promotes inflammation by binding to the IL-36 receptor (IL-
36R) and stimulating the production of a number of cytokines,
chemokines, adhesion molecules, antimicrobial peptides, and
pro-inflammatory mediators (Towne et al., 2004; Vigne et al.,
2011; Gresnigt and van de Veerdonk, 2013). Triggering IL-
36R is necessary for IL-36γ to activate pathways that lead
to induction of pro-inflammatory cytokine expression via NF-
κB and MAPKs pathways (Chustz et al., 2011; Towne et al.,
2011).
Vaginal and endocervical EC express pattern recognition
receptors (PRRs) that can be triggered by sensing microbial
products associated with bacteria and viruses resulting in an
innate immune response (Herbst-Kralovetz et al., 2008). EC
of the lower FRT respond to microbial products by secreting
cytokines, chemokines, and antimicrobial peptides (Hjelm et al.,
2010; Radtke et al., 2012; Doerflinger et al., 2014). Toll-like
receptors (TLRs) expressed in FRT EC recognize microbe-
associated molecular patterns (MAMPs) that correspond to
highly conserved microbial products. Recent studies have shown
that TLR agonists including polyinosinic-polycytidylic acid [poly
(I:C); viral product] and flagellin (bacterial product) upregulate
IL-36γ production in human skin keratinocytes, but have
differential effects on IL-36γ secretion (Lian et al., 2012). Similar
to IL-1β and IL-18, the IL-36 family members require processing
to gain full bioactivity, the enzyme required is yet to be identified
(Towne et al., 2011; Gabay and Towne, 2015). While both
microbial products induce IL-36γ expression, only poly (I:C)
has been shown to induce secretion (Lian et al., 2012). As FRT
EC express TLRs 2, 3, 5, and 6 at the highest levels (Herbst-
Kralovetz and Pyles, 2006), we tested poly (I:C; TLR3 agonist),
flagellin (TLR5 agonist), and FSL-1 (bacterial product; TLR2/6
agonist) for induction and secretion of IL-36γ in the human
FRT.
To investigate the function and regulation of IL-36γ in the
FRT, we used our well-characterized 3-D human vaginal and
endocervical EC models (Barrila et al., 2010; Hjelm et al., 2010;
Radtke et al., 2012; Doerflinger et al., 2014). These models
faithfully recapitulate many of the physiologic traits of FRT
EC, including cellular architecture, adhesion, interaction, and
immune function (Hjelm et al., 2010; Radtke et al., 2012;
McGowin et al., 2013; Doerflinger et al., 2014). Furthermore,
these two models can be used to evaluate site-specific differences
in the magnitude and/or pattern of immune response at these
sites. FRT EC models were exposed to microbial products
to measure innate inflammatory responses in the FRT via
induction and secretion of IL-36γ. In addition, we investigated
the autocrine function of IL-36γ in these 3-D FRT human EC
by treating with rIL-36γ. This is the first report to demonstrate
that IL-36 receptor and IL-36γ are both expressed by ECs
lining the human lower FRT and important in regulating host
defense and immune responses in a TLR and site-specific
manner.
MATERIALS AND METHODS
Culturing 3-D Human Vaginal and
Endocervical Epithelial Cells
Human endocervical (A2) ECs were added to a suspension of
collagen-coated dextran microcarrier beads (Sigma-Aldrich, St.
Louis, MO, USA) in KSFM (Life Technologies, Grand Island, NY,
USA) supplemented with 5 ng/ml human recombinant epidermal
growth factor, 500 µg/ml bovine pituitary extract, 44 µg/ml
CaCl2 (Sigma-Aldrich), and 100 µg/ml primocin (InvivoGen,
San Diego, CA, USA) as previously described (Radtke et al.,
2012). Human vaginal (V19I) EC were added to a suspension
of collagen-coated dextran microcarrier beads in a 1:1 mixture
of supplemented KSFM and EpiLife medium (Life Technologies)
as previously described (Hjelm et al., 2010). Cell and bead
suspensions were transferred into a slow turning lateral vessel
bioreactor and incubated at 37◦C as previously described (Hjelm
et al., 2010; Radtke and Herbst-Kralovetz, 2012; Radtke et al.,
2012). After 28 days of growth, differentiated endocervical and
vaginal aggregates were quantified using a Countess machine
(Life Technologies) and viability was measured by trypan blue
exclusion.
Human Cervical and Vaginal Epithelial
Tissue Total RNA and Protein
Human cervical and vaginal total protein samples and human
cervical and vaginal total RNA samples were purchased from
BioChain (Newark, CA, USA). According to BioChain, human
vaginal total protein and total RNA samples were acquired
from a post-menopausal Caucasian female. Human cervical total
protein samples were acquired from a pre-menopausal Asian
female and human cervical total RNA samples were acquired
from a pre-menopausal Caucasian female (BioChain). As per
Biochain, all analyzed tissues were determined to be non-
diseased per the clinical report and were screened by serology
for HIV, HBV, HCV, and HTLV. cDNA was synthesized from
total RNA (1 µg) cDNA by reverse transcription (iScript cDNA
Synthesis Kit, Bio-Rad, Hercules, CA, USA) prior to qRT-PCR
assays.
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TLR Agonist and Cytokine Treatment
For all experimental treatments, 3-D aggregates were transferred
into 24-well plates (1 × 105–5 × 105 cells per ml). Both 3-D
vaginal EC and 3-D endocervical EC were treated with poly
(I:C; InvivoGen) at 1, 25, and 100 µg/ml, flagellin (InvivoGen)
at 0.5 and 5 µg/ml, FSL-1 (InvivoGen) at 0.01 and 0.1 µg/ml,
or recombinant IL-36γ (PeproTech, Rocky Hill, NJ, USA) at 1,
10, 100, and 500 ng/ml for 24 h at 37◦C. Additional wells were
treated with sterile Dulbecco’s PBS to provide a negative control.
Following cell culture treatment, supernatants were harvested
and stored at −20◦C until analysis. Cell pellets were stored at
−20◦C in lysis buffer for RNA or protein extraction.
Protein Extraction and Quantification
For protein extraction, aggregates were pelleted and stored
at −20◦C in 1 ml of RIPA buffer [150 mM NaCl (Thermo
Fisher Scientific), 50 mM Tris-HCL pH 8.0 (Life Technologies),
1 mM EDTA (Life Technologies), 1% NP-40 (Sigma-Aldrich),
1% sodium deoxycholate (Sigma-Aldrich), 0.1% SDS (Sigma-
Aldrich), 1 mM PMSF (Sigma-Aldrich), and 5 µg/ml leupeptin
(Sigma-Aldrich)]. Frozen cell pellets were thawed on ice. Once
thawed, cells were incubated for 10 min on ice with intermittent
mixing by inversion. Next, cells were sheared with a 23-gage
needle connected to a 1 ml syringe. After incubating on ice for
20 min, cells were pelleted at 10,000 × g and supernatant was
removed. A Bradford assay was performed in a microtiter plate
to determine total protein concentration of the extracted cell
pellet and culture supernatant. Absorbance was read at 595 nm
on a Biotek ELx800 Microplate Reader (BioTek, Winooski, VT,
USA) and experimental values were compared to the calculated
standard curve to acquire total protein concentration.
ELISA Quantification of Intracellular and
Secreted Human IL-36γ
High binding microtiter plates (Corning, Tewksbury, MA, USA)
were coated with 50 µl/well of monoclonal rat anti-human IL-
36γ antibody (R&D Systems, Minneapolis, MN, USA) at 2 µg/ml
in PBS and incubated overnight at 4◦C. The microtiter plates
were washed three times with PBS-0.05%Tween-20 (PBST) then
50 µl of twofold serial dilutions of recombinant human IL-
36γ (rIL-36γ, PeproTech) was added in duplicate to generate a
standard curve. Experimental samples were added to each well
in duplicate and all samples were incubated for 2 h at 37◦C.
The microtiter plates were then washed three times with PBST
then biotinylated polyclonal goat anti-human IL-36γ detection
antibody (R&D Systems) diluted at 2 µg/ml with 1% skim milk
in PBST was added to each well and incubated for 2 h at 37◦C.
Following the incubation, the plates were washed with PBST three
times. After washing, 50 µl streptavidin-HRP (R&D Systems) was
added at a 1:250 dilution in PBST to each well and incubated
for 1 h at 37◦C. The plates were washed three times with PBST
and then developed by addition of 50 µl tetramethylbenzidine
substrate solution (Thermo Fisher Scientific, Waltham, MA,
USA) to each well and incubated in the dark for up to 30 min
at room temperature. The colorimetric reaction was stopped by
addition of 50 µl/well of 1 M phosphoric acid and absorbance
read at 450 nm on a Biotek ELx800 Microplate Reader (BioTek).
Results were reported in fold as compared to PBS treated cell
extracts.
Human IL-36γ Western Blot Analysis
Cell culture supernatants and cell pellet extracts were boiled for
10 min in 2× SDS buffer (6% SDS, 25 mM Tris-HCL pH 6.5, 10%
glycerol, 0.1 M DTT, 20 µg/ml bromophenol blue). Total protein
(30 µg) was loaded into 4–15% polyacrylamide Mini-PROTEAN
TGX precast gels (Bio-Rad). After proteins were separated by
SDS-PAGE, gels were transferred to polyvinylidene diflouride
membranes (Life Technologies) using a dry blotting system
(iBlot, Life Technologies). Levels of IL-36γ were determined
using biotinylated goat anti-human IL-36γ diluted to 4 µg/ml
in PBST with 1% dry milk, followed by streptavidin-HRP
diluted 1:250 (R&D Systems). Levels of β-tubulin were examined
using mouse anti-β-tubulin (Santa Cruz, Biotechnology, Dallas,
TX, USA) diluted 1:1000 with horseradish peroxidase labeled
goat anti-mouse (Santa Cruz Biotechnology) as a secondary
antibody. Membranes were developed using ECL substrate (Life
Technologies).
Quantification of Human Cytokines and
Chemokines by Multiplex Analysis
Supernatants from 3-D vaginal and endocervical EC aggregates
treated with rIL-36γ as described above were collected cytokine
secretion levels were quantified. Cytokine concentrations were
determined using a custom four-plex human cytokine kit
containing IL-1B, IL-6, CCL20, and TNFα (EMD Millipore,
Billerica, MA, USA) using the manufacturer’s protocol. The data
were collected using a Bio-Plex 200 System with Bio-Plex 5.0
Manager software (Bio-Rad).
RNA Extraction and Quantitative
Real-Time PCR Analysis
RNA was extracted from 3-D endocervical and 3-D vaginal
EC using the Qiagen RNeasy kit following the manufacturer’s
instructions (Qiagen, Valencia, CA, USA). cDNA was synthesized
from 1 µg RNA by reverse transcription (iScript cDNA Synthesis
Kit, Bio-Rad) and analyzed by qRT-PCR. qRT-PCR was
performed with an Applied Biosystems 7500 Fast Real Time
PCR System (Life Technologies) using customized primers
purchased from IDT (Integrated DNA Technologies, Coralville,
IA, USA) and iTAQ Universal SYBR Green Supermix (Bio-
Rad). The following primers were used in this study: IL-1β
forward, 5′-ACAGATGAAGTGCTCCTTCCA-3′ and reverse
5′-GTCGGAGATTCGTAGCTGGAT-3′ (Stordeur et al., 2002),
HE4 forward 5′-CGGCTTCACCCTAGTCTCAG-3′ and
reverse 5′-AAAGGGAGAAGCTGTGGTCA-3′ (Drapkin et al.,
2005), IL-36γ forward 5′-CCCAGTCACTGTTGCTGTTA-3′
and reverse 5′-CAGTCTTGGCACGGTAGAAA-3′, IL-36R
forward 5′-GCTGGAGTGTCCACAGCATA-3′ and reverse
5′-GCGATAAGCCCTCCTATCAA-3′ (Mutamba et al., 2012).
IL-6, IL-8, HBD2, HBD4, and SLPI primers were previously
described (Radtke et al., 2012; Doerflinger et al., 2014). Relative
transcript levels were determined using a GAPDH housekeeping
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gene transcript and are reported as fold relative to negative
control unless otherwise noted.
Statistical Analysis
All of the data for this study was generated using three
independent batches of 3-D endocervical or vaginal EC
aggregates in three independent experiments, and an average
of all three of these experimental results are presented. An
unpaired two-tailed Student t-test with Welch’s correction was
performed to determine statistical significance. GraphPad Prism
v5.0 software was used for statistical analysis (GraphPad, San
Diego, CA, USA). Levels of significance are reported as follows;
ˆP < 0.05; ∗P < 0.01; ∗∗P < 0.001.
RESULTS
Human Tissue and 3-D Vaginal and
Endocervical EC Express IL-36γ and
IL-36R
IL-36γ has been previously shown to be expressed in skin and
ECs lining mucosal tissue (Jensen, 2010; Chustz et al., 2011;
Gabay and Towne, 2015), however, this cytokine has not been
shown to be expressed previously in the FRT. Human IL-36γ
levels were measured in both 3-D vaginal and endocervical EC
by qRT-PCR analysis. Untreated 3-D vaginal and endocervical
EC, and human cervical and vaginal tissue were analyzed by
qRT-PCR assays targeting IL-36γ and IL-36R (Figure 1A). Basal
expression of IL-36γ was significantly (P < 0.001) higher in
3-D endocervical EC compared to 3-D vaginal EC. Human
3-D vaginal and endocervical EC, as well as, human vaginal
and cervical tissue expressed IL-36γ at levels much higher than
IL-36R (Figure 1A). This is the first report to characterize IL-36R
and IL-36γ in the EC lining the human FRT, furthermore, these
results demonstrate our model’s ability to serve as a tool to further
study IL-36 function.
Western blots were performed to confirm production/
synthesis of human IL-36γ in EC of the FRT. Cell lysates
from human 3-D vaginal and endocervical EC models and cell
lysates from human cervical and vaginal tissue, were analyzed
by Western blot (Figure 1B). We found that IL-36γ was
constitutively produced in human 3-D vaginal and endocervical
EC and vaginal and endocervical tissue. Basal synthesis of IL-36R
was lower than the detection limits of Western blot analysis (data
not shown) in both PBS treated and TLR agonist stimulated FRT
EC cells. TNFα, a cytokine previously shown to induce IL-36γ
(Friedrich et al., 2014), was used as a positive control to test if IL-
36γ is inducible in the FRT EC. Three-D vaginal and endocervical
EC were treated with TNFα for 24 h. Following TNFα treatment,
IL-36γ gene expression levels in 3-D vaginal and endocervical
EC were significantly (P < 0.001) increased 32-fold, and 19.6-
fold respectively (Figure 1C). The 3-D vaginal EC and tissue
exhibited higher baseline levels of IL-36γ and IL-36R relative to
3-D endocervical EC and tissue and TNFα treatment induced
higher levels of IL-36γ expression in 3-D vaginal EC relative to
the endocervical EC.
Microbial Products Differentially Induce
IL-36γ Expression and Secretion in EC of
the Human FRT
Microbial products elicit potent immune responses in EC of
the FRT through ligation with TLRs. We have previously
shown that TLR agonists: poly(I:C; viral product and TLR3
agonist), flagellin (bacterial product and TLR5 agonist), and
FIGURE 1 | Human 3-D vaginal and cervical epithelial cells and tissue express IL-36γ and IL-36R. (A) Expression of IL-36γ and IL-36R in 3-D human
vaginal and endocervical cell cultures, and human vaginal and cervical tissue. cDNA from cell cultures and tissue were analyzed by qRT-PCR and mRNA copy
numbers were normalized against GAPDH. (B) Cell lysates from 3-D vaginal and endocervical cell cultures, vaginal tissue and cervical tissue were evaluated by
Western blot for expression of IL-36γ. β-tubulin was used as a loading control. 30 µg total protein from each lysate was loaded. (C) TNFα (100 ng/ml) treated 3-D
cultures of vaginal and endocervical epithelial cells expressed IL-36γ. mRNA levels were normalized against GAPDH and expression of IL-36γ was reported as fold
change compared to PBS treated samples. Data are shown as mean ± SD from three independent experiments each performed in duplicate. ˆP < 0.05; ∗P < 0.01;
∗∗P < 0.001; unpaired two-tailed Student t-test with Welch’s correction.
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FSL-1 (bacterial product and TLR2/6 agonist) induce cytokine
expression and secretion in primary and immortalized vaginal
and endocervical EC grown as monolayers and in 3-D (Herbst-
Kralovetz et al., 2008; Hjelm et al., 2010; Radtke et al., 2012;
Doerflinger et al., 2014). These studies have also shown that TLRs
2, 3, 5, and 6 are abundantly expressed in these cell lines and these
TLRs remain functional and responsive when cultured under
rotating conditions (Herbst-Kralovetz et al., 2008; Hjelm et al.,
2010; Radtke and Herbst-Kralovetz, 2012; Radtke et al., 2012).
Maximal cytokine induction was detected 24 h after treatment
of microbial products in these studies, hence we focused on
that time point herein (Herbst-Kralovetz et al., 2008). Human
3-D vaginal and endocervical EC were treated with a panel
of microbial products for 24 h, and IL-36γ expression levels
were quantified by qRT-PCR analysis (Figure 2). Following poly
(I:C), FSL-1, and flagellin treatment did not result in cellular
adherence to beads as observed by light microscopy and cellular
viability was not decreased by more than 10% as measured
by trypan blue exclusion (data not shown). IL-36γ expression
increased following treatment with each microbial product in a
concentration dependent manner. We observed that poly (I:C)
FIGURE 2 | Differential IL-36γ induction in 3-D human vaginal and
endocervical epithelial cells treated with microbial products. Gene
expression analysis of 3-D vaginal and endocervical EC. Cell cultures were
exposed to microbial products [poly (I:C); 1, 25, and 100 µg/ml, flagellin (FLA);
0.5 and 5 µg/ml, and fibroblast stimulating lipopeptide-1 (FSL-1); 0.01 and
0.1 µg/ml] for 24 h. Expression of IL-36γ was determined by qRT-PCR and
reported relative to GAPDH as fold change compared to PBS treated
samples. Horizontal dashed line indicates IL-36γ expression in PBS treated
cells. Data are shown as mean ± SD from three independent experiments
each performed in duplicate. ˆP < 0.05; ∗P < 0.01; ∗∗P < 0.001; unpaired
two-tailed Student t-test with Welch’s correction.
induced the highest amount of IL-36γ gene expression in both
cell types (Figure 2). In 3-D vaginal EC IL-36γ expression
was induced by treatment with poly (I:C; 100 µg/ml), flagellin
(5 µg/ml), and FSL-1 (0.1 µg/ml) by 10.2-, 5.1-, and 8.9-fold,
respectively. Endocervical EC treated with poly (I:C), flagellin,
and FSL-1 also resulted in significant increases (P < 0.001) in IL-
36γ expression levels at 20.2-, 11.7-, and 7-fold, respectively. Poly
(I:C) and flagellin induced higher levels of IL-36γ expression in
3-D endocervical EC relative to vaginal EC (P < 0.001).
Since IL-36γ mRNA levels increased in a dose dependent
manner, we performed an IL-36γ targeted ELISA to quantify
protein levels following treatment with these microbial products.
After treatment with the poly (I:C), flagellin, FSL-1, and PBS,
cell lysates and cellular supernatants were collected and assayed
for IL-36γ by ELISA. Poly (I:C), flagellin, and FSL-1 treatments
induced IL-36γ production in a dose dependent manner in both
3-D vaginal and 3-D endocervical EC when compared to PBS
treated controls (Figure 3B). All of the microbial products tested
induced an increase in IL-36γ mRNA in 3-D FRT EC, however,
the magnitude of protein production and secretion levels were
microbial product specific. Treatment with higher concentrations
of poly (I:C) resulted in higher levels of secreted IL-36γ in 3-
D vaginal and endocervical EC (Figures 3A,B) when measured
by ELISA. Flagellin induced a significant increase (P < 0.01)
in intracellular IL-36γ production in vaginal and endocervical
(P < 0.01) EC. Poly (I:C) induced significant levels of IL-36γ
secretion by vaginal (1 µg/ml; P< 0.01, 25 µg/ml; P< 0.001, and
100µg/ml; P< 0.001) and endocervical (1µg/ml; [not significant
(NS)] 25 µg/ml; P < 0.001, and 100 µg/ml; P < 0.001) EC.
FSL-1 induction of intracellular IL-36γ production significantly
increased secretion of IL-36γ in both vaginal (0.01 µg/ml;
P < 0.01, 0.01 µg/ml; P < 0.001) and endocervical (0.01 µg/ml;
P < 0.01, 0.01 µg/ml; P < 0.001) EC. Less IL-36γ secretion
occurred following treatment with flagellin relative to control
treated cells.
IL-36γ probed Western blots were performed to verify
ELISA results. FRT EC were treated with poly (I:C), flagellin,
and FSL-1 in increasing concentrations for 24 h. Both the
supernatant and extracted cell pellets of TLR agonist treated
FRT EC were analyzed to measure intracellular and secreted
IL-36γ levels. Patterns of IL-36γ protein synthesis detected
by Western blot mirrored the quantitative data generated by
ELISA, supporting the protein production profiles of FRT EC
(Supplementary Figure S1). Poly (I:C) and FSL-1 treatment
resulted in the highest induction of secreted IL-36γ levels relative
to untreated wells by ELISA and Western blot, whereas flagellin
treatment induced significantly higher intracellular levels of IL-
36γ (Figure 3 and Supplementary Figure S1). As such, there
was an inverse relationship between IL-36γ induction by these
microbial products.
Recombinant IL-36γ Induces an
Autocrine IL-36γ Loop in Human 3-D
Vaginal and Endocervical EC
IL-36γ has been shown to induce expression of itself, thereby
exhibiting an autocrine signaling loop in keratinocytes (Lian
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FIGURE 3 | Extracellular and intracellular localization of IL-36γ in epithelial cells of the human female reproductive tract following treatment with
microbial products. Three-D vaginal and endocervical EC were treated with PBS, flagellin (FLA; 5 or 0.5 µg ml−1), FSL-1 (0.1 or 0.01 µg ml−1), or poly (I:C; 100,
25, or 1 µg ml−1) for 24 h. (A) Cell culture lysates and (B) supernatants were assayed by ELISA to quantify IL-36γ production and secretion. Levels of IL-36γ were
determined and reported as fold change relative to PBS treated samples. Horizontal dashed line indicates IL-36γ expression in PBS treated cells. Data are shown as
mean ± SD from three independent experiments each performed in duplicate. ˆP < 0.05; ∗P < 0.01; ∗∗P < 0.001; unpaired 2-tailed Student t-test with Welch’s
correction.
et al., 2012). Three-D vaginal and endocervical EC were treated
with increasing doses of rIL-36γ (1, 10, 100, and 500 ng/ml)
for 24 h. qRT-PCR assays targeting IL-36γ and IL-36R was
performed following treatment with rIL-36γ. We observed a
significant increase in IL-36γ gene expression in both 3-D vaginal
(10 ng/ml; P< 0.001, 100 ng/ml; P< 0.001, 500 ng/ml; P< 0.001)
and endocervical EC (10 ng/ml; P < 0.01, 100 ng/ml; P < 0.001,
500 ng/ml P < 0.001; Figure 4A). A similar pattern in IL-
36R expression in 3-D vaginal [10 ng/ml; 4.2-fold (P < 0.01),
100 ng/ml; 7.9-fold (P< 0.001), 500 ng/ml; 10.4-fold (P< 0.001)]
and endocervical EC [10 ng/ml; 8.3-fold (P < 0.05), 100 ng/ml;
13.9-fold (P< 0.01), 500 ng/ml; 15.7-fold (P< 0.001; Figure 4B)]
was observed, albeit at lower levels. The fold increases in
both IL-36γ and IL-36R were dependent on rIL-36γ treatment
concentration and expression levels were higher in the 3-D
endocervical EC compared to the vaginal EC.
Pro-inflammatory Cytokine and
Antimicrobial Peptide Production in 3-D
FRT EC is Increased Following
Recombinant IL-36γ Treatment
We have shown that microbial products induce IL-36γ and
influence its secretion. To examine the role IL-36γ plays in
triggering inflammatory signaling pathways in FRT EC and
to determine if it is concentration dependent, we treated
3-D endocervical and vaginal EC with rIL-36γ. Treatment
with rIL-36γ induced antimicrobial peptide, pro-inflammatory
cytokine, and chemokine production in a dose dependent
manner (Figures 5 and 6). IL-8 (Figure 5A) mRNA levels were
significantly increased (P < 0.001) in both cell models following
100 and 500 ng/ml rIL-36γ treatments. rIL-36γ treatment
(500 ng/ml) resulted in a significant difference (P < 0.001) in
CCL20 production (Figure 5B) and 3-D vaginal EC CCL20 levels
were significantly higher (P < 0.001) at 500 ng/ml compared
to the 3-D endocervical EC. Antimicrobial peptides including
HE4 (Figure 5C), SLPI (Figure 5D), HBD-2 (Figure 5E), and
HBD-4 (Figure 5F) were significantly increased in a dose
dependent manner following rIL-36γ treatments. Treatment
with rIL-36γ at 100 and 500 ng/ml resulted in significant
increases in HE4 in 3-D vaginal (P < 0.001 and P < 0.01)
and endocervical (P < 0.05 and P < 0.001). SLPI mRNA levels
increased at similar magnitudes following rIL-36γ treatments at
100 and 500 ng/ml in 3-D vaginal (P < 0.001) and endocervical
(P < 0.05) EC.
Of these AMP, two notable site-specific differences were
observed in the induction HBD-2 and HBD-4 in 3-D FRT
EC following treatment with100 and 500 ng/ml of rIL-36γ.
Fold values for 3-D vaginal cells were higher for HBD-2 and
HBD-4 relative to endocervical EC. HBD-2 increased 12.7-fold
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FIGURE 4 | Induction of IL-36γ and IL-36R expression following recombinant IL-36γ treatment. 3-D vaginal and endocervical EC were treated with
increasing doses of recombinant IL-36γ (1, 10, 100, and 500 ng/ml) for 24 h. (A) IL-36γ and (B) IL-36R expression was determined by qRT-PCR and reported
relative to GAPDH as fold change compared to PBS treated samples. Horizontal dashed line indicates IL-36γ expression in PBS treated cells. Data are shown as
mean ± SD from three independent experiments each performed in duplicate. ˆP < 0.05; ∗P < 0.01; ∗∗P < 0.001; unpaired two-tailed Student t-test with Welch’s
correction.
(P < 0.001) and 39.4-fold (P < 0.001) and HBD-4 mRNA was
increased 24.6-fold (P < 0.001) and 55.4-fold (P < 0.001) in 3-
D vaginal EC, respectively. rIL-36γ treated 3-D endocervical EC
increased 6.9- and 18-fold at 100 and 500 ng/ml, respectively, for
HBD-2 at 15.6-fold (P < 0.001) and 31.8-fold (P < 0.001) for
the HBD-4 gene. HBD 2 and HBD-4 expression was significantly
higher in 3-D vaginal EC than 3-D endocervical EC following rIL-
36γ treatments at 100 and 500 ng/ml (P < 0.05 and P < 0.01
respectively). SLPI and HE4, were the only AMP assayed that
resulted in more robust response in endocervical EC when
compared to vaginal EC, but these site specific differences in
expression were not significant. IL-8 gene expression levels were
similar in both cell types. CCL20 expression levels varied in the
two cell types depending on the concentration of rIL-36γ.
We have shown that rIL-36γ increases gene expression
of chemokines and AMP. To quantify levels of additional
proinflammatory cytokines and chemokines we assayed cell
supernatants with a multiplex bead-based immunodetection
assay. Secretion of IL-1β, IL-6, CCL20, and TNFα was induced
in a dose dependent fashion following 24 h treatments with rIL-
36γ (Figure 6). CCL20 secretion was significantly (P < 0.01)
increased following treatment with rIL-36γ at 100 and 500 ng/ml
in both 3-D vaginal and endocervical EC. IL-1β secretion was
significantly (P < 0.01) increased following rIL-36γ treatments
at 500 ng/ml in 3-D vaginal EC. rIL-36γ treatments at 100 and
500 ng/ml resulted in significant increases in IL-1β secretion
(P < 0.05) in 3-D endocervical EC as well. Secretion of IL-
6 was significantly (P < 0.01) increased in 3-D vaginal EC
following rIL-36γ treatments of 100 and 500 ng/ml. IL-6 and
TNFα secretion was induced in 3-D endocervical EC, however,
the magnitude of secretion was higher in 3-D vaginal EC.
Secreted IL-6 increased from 86.48 to 552.9 pg/ml (NS) for
100 ng/ml rIL-36γ and 951.5 pg/ml (P < 0.01) for 500 ng/ml
rIL-36γ. TNFα levels from 3-D endocervical EC increased only
slightly following rIL-36γ treatments and the increase was not
significant. Overall, pro-inflammatory cytokines, chemokines,
and AMP were significantly induced in 3-D vaginal and cervical
EC following treatment with rIL-36γ. The pattern of cytokine and
AMP induction was similar for vaginal and cervical cells and was
also dose-dependent, but the magnitude was higher in the 3-D
vaginal EC model relative to the 3-D cervical model for most
immune mediators evaluated.
DISCUSSION
This is the first report demonstrating a role for IL-36γ
in host defense and amplification of the mucosal immune
response by ECs lining the FRT. We showed that in the
lower FRT, IL-36γ stimulates the innate immune response
by induction of pro-inflammatory cytokines, chemokines, and
AMP, thereby promoting mucosal inflammation. This study
provides the foundation for future studies that aim to
elucidate the mechanisms of IL-36 family members in the FRT
during homeostasis, STI, disease pathogenesis, and reproductive
sequelae.
Recent literature on IL-36γ has been primarily focused
on chronic inflammatory processes that include psoriasis and
chronic obstructive pulmonary disease (COPD), where IL-36γ
was found to be abundantly expressed in the skin and the mucosal
ECs of the lung (Li et al., 2014; Gabay and Towne, 2015) and
result in sustained inflammation (Chustz et al., 2011; Gabay
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FIGURE 5 | Recombinant IL-36γ treatment induces antimicrobial peptide expression in 3-D human vaginal and endocervical epithelial cells. 3-D
vaginal and endocervical cell cultures were treated with increasing doses of recombinant IL-36γ (1, 10, 100, or 500 ng/ml) for 24 h. Relative expression levels of
(A) IL-8, (B) CCL20, (C) HE4, (D) SLPI, (E) HBD-2, and (F) HBD-4 were determined by qRT-PCR and reported relative to GAPDH as fold change compared to PBS
treated cells Data are shown as mean ± SD from three independent experiments each performed in duplicate. ˆP < 0.05; ∗P < 0.01; ∗∗P < 0.001; unpaired
two-tailed Student t-test with Welch’s correction.
and Towne, 2015). However, there have been limited studies
investigating the role of IL-36γ in host defense and infection at
mucosal sites (Vos et al., 2005; Gresnigt et al., 2013; Segueni et al.,
2015).
Herein we report that IL-36γ is expressed in human cervical
and vaginal ECs and tissue. A limitation to the study evaluating
IL-36γ and IL-36R in vaginal tissue, is the lack of availability
of premenopausal non-diseased vaginal tissue. However, our
data demonstrated that premenopausal cervical tissue and
post-menopausal vaginal tissue both express IL-36γ and IL-
36R. Future studies will be required to determine the impact
of sex hormones on this cytokine and associated receptor
expression. Using our well-characterized human 3-D cervical
and vaginal EC models we demonstrate that these cells respond
to rIL-36γ exposure in a site-specific manner. Overall, 3-D
vaginal EC expressed and secreted higher levels of these innate
immune mediators following rIL-36γ treatments relative to
3-D endocervical EC, however, this response did not seem to
correspond to IL-36R expression (Figure 1).
IL-36γ increases and prolongs inflammation through
interaction with TNFα, a known inducer and inductee of IL-36γ
(Towne and Sims, 2012). TNFα is expressed in excess in psoriatic
lesions (Cuchacovich et al., 2008) leading to upregulation
of IL-36γ. IL-36γ mRNA and protein have been shown to
be induced in keratinocytes following treatment with TNFα
(Kumar et al., 2000). Consistent with findings in bronchial ECs
(Chustz et al., 2011), IL-36γ levels were increased following
TNFα treatment in 3-D FRT EC, demonstrating that expression
of IL-36γ is inducible in the human FRT. TNFα and IL-36γ
participate in a mutually reinforcing gene expression loop,
initiated by IL-36γ, TNFα, as well as other cytokines (Friedrich
et al., 2014). Increased levels of TNFα have been shown to result
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FIGURE 6 | 3-D human vaginal and endocervical epithelial cells secrete increased levels of pro-inflammatory cytokines and chemokines in response
to treatment with recombinant IL-36γ. 3-D vaginal and endocervical cell cultures were treated with PBS or increasing doses of recombinant IL-36γ (1, 10, 100,
or 500 ng/ml) for 24 h. Expression levels of (A) IL-1β, (B) IL-6, (C) TNFα, and chemokine (D) CCL20 were determined by multiplex analysis and reported in pg/ml.
Data are shown as mean ± SD from three independent experiments each performed in duplicate. ˆP < 0.05; ∗P < 0.01; ∗∗P < 0.001; unpaired two-tailed Student
t-test with Welch’s correction.
from microbial product exposure and pathogenic insults in the
FRT (Jarvis et al., 1999; Agrawal et al., 2008; Hjelm et al., 2010;
Radtke et al., 2012; Krzyzowska et al., 2013; Doerflinger et al.,
2014) and as such, IL-36γ could be bolstering the inflammatory
cascade in the FRT.
Poly (I:C), FSL-1, and flagellin treatments each resulted in
unique IL-36γ expression and secretion patterns in our 3-D FRT
EC models. TLR2, 3, 5, and 6 are the most abundantly expressed
and functional in the FRT and our 3-D human FRT models
(Herbst-Kralovetz et al., 2008; Hjelm et al., 2010; Radtke and
Herbst-Kralovetz, 2012; Radtke et al., 2012). Flagellin targets
TLR5, which activates the pro-inflammatory NF-κB pathway
in parallel to apoptotic caspase cascades (Zeng et al., 2006).
FSL-1 signals through TLR2/6, which also leads to the pro-
inflammatory NF-κB pathway, but also triggers the MAPK
pathway leading to possible apoptosis through MyD88 and
caspase 8 (Aliprantis et al., 2000). Increased levels of IL-36γ
were detected in 3-D FRT EC cell culture supernatant following
FSL-1 treatment, but not following flagellin treatment. The
mechanism of secretion is unclear as IL-36γ lacks a conventional
signal sequence (Towne et al., 2011), and further work must
be performed to determine IL-36γ secretion mechanisms in
FRT EC. Poly (I:C) triggers TLR3 in the endosome, activating
inflammation through the NF-κB pathway. Poly (I:C) has also
been shown to induce FRT EC pro-inflammatory cytokine
secretion, recruiting immune cells that activate cellular defense
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mechanisms, limiting viral replication until an adaptive immune
response is generated (Schaefer et al., 2005; Herbst-Kralovetz
and Pyles, 2006). It is unclear whether poly (I:C) induces IL-36γ
secretion via a signaling sequence or via cell death, but it is
possible that IL-36γ acts as an alarmin, alerting surrounding cells
of danger (Lian et al., 2012).
In our study, levels of extracellular IL-36γ significantly
increased and intracellular IL-36γ decreased following high dose
treatments with poly (I:C). In contrast, flagellin treatment in
FRT EC resulted in increased intracellular IL-36γ protein with
corresponding supernatants containing low levels of extracellular
IL-36γ. These results are similar to IL-36γ expression patterns
observed in a study by Lian et al. in keratinocytes (Lian et al.,
2012). These microbial product-specific induction and secretion
relationships suggest that IL-36γ influences TLR dependent
cellular defense responses unique to different forms of microbial
attack. Further studies are required, but our data suggest that IL-
36γ secretion may play a role in antimicrobial host defense and
regulating tissue specific immune responses to infection in the
FRT by amplifying the mucosal immune response.
IL-36γ activates the release of cytokines and chemokines
from surrounding cells, leading to inflammatory host defense
against invading pathogens. Prolonged inflammation in the FRT
may also act as a warning sign of infection, indicating that
IL-36γ may act as a marker for FRT disease or inflammation.
A recent proteomics report demonstrated that cervicovaginal
lavages collected from women with bacterial vaginosis exhibited
elevated levels of IL-36α and IL-36 receptor antagonist relative
to controls, further supporting a role for IL-36 family members
in the FRT (Borgdorff et al., 2015). Both 3-D vaginal and
endocervical EC responded to rIL-36γ treatment by upregulating
gene expression of IL-6, IL-8, IL-1β, and TNFα. Each of these
immune mediators has been found to be elevated in human
cervicovaginal lavages collected from women with STI (Trifonova
et al., 2007; Kyongo et al., 2015), as well as in the cell lines used
in our 3-D FRT EC cultures following STI exposure (Herbst-
Kralovetz et al., 2008; Hjelm et al., 2010; Radtke and Herbst-
Kralovetz, 2012; McGowin et al., 2013). However, preliminary
studies have not shown significant changes in TLR expression
following rIL-36γ treatment (data not shown). We found that
treating the 3-D FRT EC with rIL-36γ induced expression of
IL-36R and cellular IL-36γ. A study by Friedrich et al. with
keratinocytes defined this autocrine function as a self-amplifying
loop involving IL-17 (Friedrich et al., 2014). IL-36γ has also been
shown to induce CCL20, a Th17 cytokine, in lung fibroblasts due
to asthma and COPD (Chustz et al., 2011) and in dermatoses
via LL-37 (Li et al., 2014). rIL-36γ induced upregulation of IL-
36γ and IL-36R mRNA as well as CCL20 mRNA and protein
in 3-D FRT EC models suggesting the induction of an IL-
36γ amplification loop following TLR activation. The increased
secretion of CCL20 and its impact on Th17 cell recruitment and
activation may play a role in host defense against FRT insult and
is a future area of investigation.
AMP are present in the FRT during homeostasis and
production is increased following infection in the FRT, as
detected in cervicovaginal lavages (Novak et al., 2007; Keller
et al., 2012; Madan et al., 2012; Pellett Madan et al., 2015). AMP
induction by IL-36γ has been observed in keratinocytes and
bronchial ECs (Chustz et al., 2011; Lian et al., 2012; Li et al.,
2014). We investigated a panel of AMP known to be expressed
in the lower FRT (Yarbrough et al., 2015) for induction by rIL-
36γ exposure. Our data shows that each of these AMP (CCL20,
HE4, SLPI, HBD-2, and HBD-4) were induced by treatment with
rIL-36γ, further promoting inflammation in FRT EC in a dose-
dependent fashion. CCL20, HBD-2, and HBD-4 upregulation
was more robust in 3-D vaginal EC relative to cervical EC.
Following pathological insult, serine protease inhibitors HE4
and SLPI have an inverse relationship, for example in bacterial
vaginosis, HE4 is elevated, whereas SLPI is decreased (Mitchell
et al., 2008). Interestingly, rIL-36γ treatment induced HE4 and
SLPI expression in 3-D FRT models, similar to IL-1 treatment
(Bingle et al., 2006). Further investigation is needed to determine
if AMP induction by IL-36γ enhances host defense or results in
damaging inflammation.
In the FRT, IL-36γ may function as a key regulator of mucosal
inflammation. This is the first study to report the induction and
regulation of IL-36γ, IL-36R, and related immune mediators in
the human FRT following microbial product exposure. Both IL-
36γ and IL-36R were induced by rIL-36γ in a dose dependent
fashion, as well as a number of AMPs, pro-inflammatory
cytokines, and chemokines in the FRT. The IL-36 family has
been associated with the pathogenesis of several inflammatory
diseases. Our data suggest that IL-36γ could play a critical
role in initiating, promoting and sustaining epithelial-mediated
inflammation to microbial products in the FRT. As such, future
work will be aimed at studying the role of the IL-36 family in
the context of the FRT in terms of host response to vaginal
microbiota, STI pathogens, and other reproductive disorders.
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